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The androgen receptor (AR) plays a critical role in male sexual development and in normal and malignant
prostate cell growth and survival. It has been shown that AR transcriptional activation is regulated through
interactions with a variety of transcriptional co-regulators.The Protein Inhibitors of Activated STATs (PIAS)
are transcriptional co-regulators, and have been shown to modulate AR-mediated transcription. In this brief,
we summarize our recent studies on two novel PIAS-like proteins, Zimp7 and Zimp10. Particularly, we address
the functional interactions between the AR and these two proteins, and potential mechanisms by which they
regulate AR mediated transcription. In addition, we explore potential roles of Zimp10 in transcriptional
regulation in vivo using a recent Zimp10 knockout mouse model.Taken together, our findings thus far suggest
that Zimp7 and Zimp10 are functionally non-redundant and share unique characteristics that have not been
described for the PIAS family. Further investigation into the functional roles of these two PIAS-like proteins
may help to better understand prostate cancer progression, and yield possible new targets for therapeutic
intervention.
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Introduction
AR-mediated transcription is a complicated process,
which is facilitated through interactions with multiple
co-regulators. Indeed, it has been suggested that
alterations in AR co-regulator expression is a mechanism
by which prostate cancers progress to an
androgen-insensitive stage [Heinlein and Chang, 2004],
highlighting the importance of understanding how
transcriptional co-regulators modulate AR activity. Over
200 nuclear hormone receptor co-regulators have been
identified in recent years [Chang and McDonnell, 2005].
Among them, the PIAS proteins have been shown to
regulate the function of the AR and other nuclear hormone
receptors [Schmidt and Muller, 2003].
The PIAS proteins were originally identified as negative
regulators of the JAK-STAT cytokine signaling pathway,
but have subsequently been shown to regulate the activity
of steroid hormone receptors and other transcription
factors, such as LEF-1, and p53 [Kotaja et al., 2000;
Nelson et al., 2001; Sachdev et al., 2001]. Of particular
relevance to AR signaling, the PIAS family member
PIASxα was first described as AR-interacting protein 3
(ARIP3) [Moilanen et al., 1999]. In addition to their role
as negative regulators of the STAT pathway, the PIAS
proteins have been shown to positively and negatively
regulate the activity of other transcription factors in
different cell contexts [Schmidt and Muller, 2003].The
PIAS proteins possess E3 ligase activity for the
ubiquitin-like SUMO pathway, and have been shown to
regulate AR activity through sumoylation of the AR and
its co-factors [Nishida and Yasuda, 2002; Schmidt and
Muller, 2002].
PIAS proteins contain a conserved zinc-binding
SP-RING/Miz domain, which is similar to the RING
domain in the RING-type E3 ubiqitin ligases [Schmidt and
Muller, 2003].This domain appears essential for
PIAS-mediated modulation of transcription because
targeted mutations within this region abrogate
SUMO-conjugating activity and interactions with target
proteins [Kahyo et al., 2001; Kotaja et al., 2002]. Recently,
we have identified two novel PIAS-like proteins that
contain the SP-RING/Miz domain [Huang et al., 2005;
Sharma et al., 2003]. Based on this feature, we have
named these proteins Zimp7 and Zimp10 (Zinc
finger-containing, Miz-1, PIAS-like protein on chromosome
7 or 10). Like the PIAS proteins, both Zimp7 and Zimp10
interact with the AR and regulate its activity. Importantly,
Zimp7 and Zimp10 have been shown to interact with
components of the SWI/SNF chromatin remodeling
complexes, suggesting a potential mechanism by which
the Zimp proteins regulate the activity of the AR or other
transcription factors.The following brief outlines our
current knowledge of Zimp7 and 10.
Zimp10 is an AR co-activator
Zimp10 was originally isolated in a yeast two-hybrid assay
using a partial AR transactivation domain as bait.
Sequence analysis revealed that Zimp10 contains 1067
amino acids and shares a highly conserved SP-RING/Miz
domain with members of the PIAS family (Figure 1a). In
addition to the SP-RING/Miz domain, Zimp10 also
contains a nuclear localization sequence (NLS) and two
proline-rich regions (Figure 1b). Interestingly, Zimp10
contains a strong intrinsic transactivation domain within
its C-terminus, a function that has also been described
for PIAS1 and Miz1 [Kotaja et al., 2000]. Zimp10 mRNA
is highly expressed in urogenital tissues, including
prostate, testis, and ovary, and in prostate and breast
cancer cell lines.
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Perspective  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1.  Sequence of the human Zimp7 and Zimp10 Miz domains A. Sequence alignment of the Miz domains of hZimp7, hZimp10, and members
of the PIAS family. Identical amino acids are indicated in bold. Comparison of the consensus sequences for the Miz finger and RING finger domains
are shown in gray. For comparison, the RING finger domains of the E3 ubiquitin ligases Cbl and MDM2 are also shown. B. Comparison of Zimp7 and
Zimp10 functional domains. Pro-rich, proline rich region; NLS, Nuclear localization sequence.
Several lines of evidence have demonstrated that Zimp10
physically interacts with the AR and augments AR
transcriptional activity [Sharma et al., 2003]. Interestingly,
Zimp10 has little or no effect on several other nuclear
hormone receptors, including the glucocorticoid receptor
(GR), estrogen receptor (ER), thyroid receptor β (TR-β),
or vitamin D receptor (VDR). Endogenous Zimp10 protein
is primarily localized to the nucleus in all cell lines and
prostate tissue samples examined. In addition,
immunofluorescent staining has shown that Zimp10
co-localizes with the AR and SUMO-1 at replication foci
during S-phase. Consistent with these observations, AR
sumoylation is enhanced in the presence of Zimp10.
Furthermore, mutation of one (K386R) or both
(K386R/K520R) of the major AR sumoylation sites
reduces Zimp10-mediated enhancement of AR activity.
Interestingly, this is in contrast with reports indicating that
PIAS-mediated AR sumoylation represses AR
transcriptional activity [Kotaja et al., 2002; Nishida and
Yasuda, 2002].
Identification of Zimp7, a Zimp10
homolog
A search for homologs of Zimp10 revealed that the KIAA
clone KIAA1886 and Zimp10 share significant sequence
similarity. Isolation of the full-length cDNA and translation
of the protein product indicated that it is an 892aa protein
with a molecular size of approximately 100kDa. A BLAST
search mapped the nucleotide sequence to chromosome
7, and we have thus named this protein Zimp7. Like
Zimp10, it contains the SP-RING/Miz domain, a NLS, a
C-terminal proline-rich region, and a C-terminal
transactivation domain. However, Zimp7 lacks the
N-terminal proline-rich region present in Zimp10 (Figure
1b). Consistent with their homology, Zimp7 and Zimp10
share many of the same functional characteristics. Zimp7
is a nuclear protein and localizes to replication foci during
S phase. Additionally, Zimp7 co-localizes with SUMO-1
and the AR in prostate tissues and several human cell
lines. However, the expression profile of Zimp7 is not
identical to that of Zimp10, and is most highly expressed
in the testis, as well as in prostate, ovary, heart, skeletal
muscle, and pancreas. Several lines of evidence have
shown that Zimp7 physically interacts with the AR and
augments AR-mediated transcription. Although the
precise differences between these two proteins are
unclear, our recent studies have shown that Zimp7 and
Zimp10 may preferentially regulate different subsets of
nuclear hormone receptors and other transcription factors
[Huang et al., 2005; Sharma et al., 2003].
Understanding the biological role of
Zimp10 in vivo
Further insight into the potential mechanisms of Zimp7/10
transcriptional regulation comes from a recent report by
Guiterrez et al., which described a Zimp7/10 ortholog in
Drosophila called tonalli (tna) [Gutierrez et al., 2003].
Interestingly, tna genetically interacts with brahma, which
encodes an ATPase subunit of the SWI2/SNF2 chromatin
remodeling complexes.These data suggest that Zimp7
and Zimp10 may regulate transcription through
modifications of chromatin structure via interactions with
SWI/SNF complexes. Intriguingly, we have observed that
both Zimp7 and Zimp10 co-localize with BrdU and/or
proliferating cell nuclear antigen (PCNA) in sub-nuclear
replication foci during S-phase. In addition,
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Perspective Zimp7 and Zimp10 in the coregulation of the ARTable 1.  Comparison of knockout phenotypes for general transcriptional co-regulators, PIAS family members, and specific transcription
factors The names, functions, and phenotypic defects of knockout mice for various genes are shown. Knockouts for Zimp10 and the general
transcriptional co-regulators p300 and Brg-1 display more severe defects than knockouts for PIAS family members, AR and p53.
co-immunoprecipitation studies have shown that Zimp7
and Zimp10 interact with Brg-1, a component of SWI/SNF
complexes. Zimp7 also associates with the SWI/SNF
subunit, BAF57, and increases Brg-1/BAF57-mediated
enhancement of AR transcriptional activity [Huang et al.,
2005].
To further characterize the biological roles of Zimp7 and
Zimp10, we have used gene-targeting strategies to disrupt
the Zimp7 and Zimp10 alleles in mice. Zimp10 knockouts
die between 9.5-10.5 days post-coitus. At this stage,
Zimp10 knockout embryos are approximately half the
size of wild type littermates and display vascular defects.
In addition, a fraction of mice heterozygous for the
disrupted Zimp10 allele do not survive, suggesting that
Zimp10 gene dosage is important for proper development.
However, the heterozygotes that do survive have no
apparent defects.The embryonic lethal phenotype is in
contrast to PIAS knockouts, which are generally viable
[Liu et al., 2004; Santti et al., 2005;Wong et al., 2004].
Loss of Zimp10 causes severe defects in cell viability
because mouse embryo fibroblasts from Zimp10 knockout
embryos show greatly reduced proliferative ability
compared to their wild type counterparts. Growth inhibition
is also observed in prostate cancer cell lines following
knock-down of endogenous Zimp10 protein by interfering
RNA.The embryonic lethality observed in Zimp10
knockouts suggests that Zimp7 cannot entirely
compensate for loss of Zimp10 function.We are currently
in the process of characterizing Zimp7 and Zimp7/Zimp10
knockouts to determine whether Zimp7 and Zimp10 have
any functional redundancy.The data from these studies
will further advance our knowledge regarding the roles
of Zimp7 and Zimp10 in vivo. Of note, mice with a
non-functional AR are viable [Quigley et al., 1995], which
indicates that Zimp10 may affect AR-independent
pathways (Table 1). Indeed, the lethal phenotype of
Zimp10 knockouts suggests a critical role for the protein
in early development, a requirement that has not been
described in knockouts for PIAS family members (Table
1) [Liu et al., 2004;Wong et al., 2004].
Conclusions
Zimp7 and Zimp10 are two novel PIAS-like proteins,
which share a highly conserved SP-RING/Miz
protein-protein interaction domain that is important for
PIAS-mediated sumoylation of target proteins. Both Zimp7
and Zimp10 contain strong intrinsic transactivation
domains and augment AR activity.The interactions
between the Zimp proteins and components of the
SWI/SNF chromatin remodeling complexes suggest a
possible role for Zimp7 and Zimp10 in chromatin
modification. Zimp10 knockout mice exhibit embryonic
lethality, a more severe phenotype compared to PIAS
knockouts and mice with a non-functional AR, which
suggests that Zimp10 may play a more general role in
transcriptional regulation and may not share redundancy
with Zimp7 or members of the PIAS family. Indeed, the
Zimp10 knockout phenotype more closely resembles
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co-factors [Bultman et al., 2000;Yao et al., 1998], rather
than knockouts for the PIAS family members [Liu et al.,
2004;Wong et al., 2004] or for specific transcription
factors [Ghebranious and Donehower, 1998;Yeh et al.,
2002]. Further characterization of Zimp7 and Zimp10
knockouts will provide greater insight into the roles of
Zimp7 and Zimp10 in vivo.
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